PubRank

Simon Lovestone

Author PubWeight™ 185.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009 15.15
2 Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011 9.23
3 Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol 2015 5.10
4 Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2007 5.09
5 Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010 3.64
6 Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol 2012 3.31
7 The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2007 3.16
8 The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry 2009 3.15
9 Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 2007 2.73
10 Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010 2.57
11 Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004 2.54
12 The dementias. Lancet 2002 2.42
13 A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet 2005 2.04
14 Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A 2004 1.95
15 Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002 1.83
16 Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet 2002 1.77
17 Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol 2008 1.74
18 Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis 2010 1.73
19 DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet 2006 1.73
20 The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet 2012 1.71
21 SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 2010 1.58
22 Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 2007 1.50
23 SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis 2007 1.49
24 Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 2012 1.46
25 Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage 2010 1.44
26 The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 2011 1.35
27 Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage 2011 1.34
28 Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 2004 1.32
29 Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 2011 1.30
30 Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis 2014 1.29
31 Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 2009 1.28
32 MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 2009 1.28
33 Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 2003 1.26
34 Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2010 1.26
35 Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med 2004 1.26
36 AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011 1.24
37 Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry 2010 1.24
38 Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet 2010 1.23
39 Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2005 1.22
40 Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet 2007 1.16
41 Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc 2006 1.15
42 Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J Alzheimers Dis 2010 1.12
43 Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010 1.12
44 Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur J Neurosci 2008 1.12
45 Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 2013 1.12
46 Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis 2012 1.11
47 Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 2008 1.11
48 Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One 2011 1.10
49 Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups--the AddNeuroMed study. Neurobiol Aging 2009 1.09
50 Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neurosci Lett 2004 1.09
51 Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2010 1.08
52 p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett 2007 1.08
53 A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. Neuroimage 2011 1.06
54 Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 2011 1.06
55 The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 2013 1.05
56 A blood gene expression marker of early Alzheimer's disease. J Alzheimers Dis 2013 1.05
57 Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Res 2013 1.05
58 A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 2008 1.04
59 Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 2005 1.04
60 Complement activation as a biomarker for Alzheimer's disease. Immunobiology 2011 1.04
61 Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet 2007 1.03
62 Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry 2012 1.02
63 The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis 2012 1.02
64 Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet 2012 1.02
65 The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 2003 1.01
66 Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease. J Alzheimers Dis 2013 1.01
67 APOE ε2 allele is associated with larger regional cortical thicknesses and volumes. Dement Geriatr Cogn Disord 2010 1.00
68 Education increases reserve against Alzheimer's disease--evidence from structural MRI analysis. Neuroradiology 2012 0.99
69 Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis 2005 0.99
70 Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis 2012 0.99
71 Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One 2012 0.98
72 Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J Alzheimers Dis 2011 0.98
73 GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci 2006 0.97
74 Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. Ann Neurol 2006 0.97
75 A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 2009 0.96
76 Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice. Int J Geriatr Psychiatry 2007 0.94
77 Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet 2007 0.93
78 OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings. Br J Psychiatry 2011 0.92
79 Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging 2012 0.92
80 Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. Am J Med Genet B Neuropsychiatr Genet 2005 0.92
81 Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am J Med Genet B Neuropsychiatr Genet 2005 0.92
82 Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 2010 0.92
83 TAp73 isoforms antagonize Notch signalling in SH-SY5Y neuroblastomas and in primary neurones. J Neurochem 2006 0.91
84 Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression. J Alzheimers Dis 2011 0.91
85 No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2011 0.91
86 Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Hum Genet 2003 0.91
87 PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Lett 2006 0.91
88 Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls. J Alzheimers Dis 2010 0.91
89 Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol 2009 0.90
90 Genetic association of the APP binding protein 2 gene (APBB2) with late onset Alzheimer disease. Hum Mutat 2005 0.90
91 Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4. Biol Psychiatry 2007 0.89
92 The NEO-FFI is a reliable measure of premorbid personality in patients with probable Alzheimer's disease. Int J Geriatr Psychiatry 2006 0.89
93 Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging 2010 0.88
94 Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiol Aging 2012 0.88
95 TAp73alpha induces tau phosphorylation in HEK293a cells via a transcription-dependent mechanism. Neurosci Lett 2006 0.88
96 Plasma biomarkers for Alzheimer's disease: much needed but tough to find. Biomark Med 2012 0.88
97 Truncated apoE forms tangle-like structures in a neuronal cell line. Neuroreport 2002 0.88
98 Nicastrin gene polymorphisms, cognitive ability level and cognitive ageing. Neurosci Lett 2005 0.88
99 Wnt3a induces exosome secretion from primary cultured rat microglia. BMC Neurosci 2012 0.87
100 Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol Aging 2011 0.87
101 Ageing increases vulnerability to aβ42 toxicity in Drosophila. PLoS One 2012 0.87
102 Smell identification function as a severity and progression marker in Alzheimer's disease. Int Psychogeriatr 2013 0.87
103 Dynamic properties of APC-decorated microtubules in living cells. Cell Motil Cytoskeleton 2003 0.86
104 Premorbid personality and behavioral and psychological symptoms in probable Alzheimer disease. Am J Geriatr Psychiatry 2007 0.86
105 CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study. J Alzheimers Dis 2010 0.86
106 The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS One 2011 0.85
107 β-Amyloid precursor protein and tau protein levels are differently regulated in human cerebellum compared to brain regions vulnerable to Alzheimer's type neurodegeneration. Neurosci Lett 2010 0.84
108 Deep sequencing of the Nicastrin gene in pooled DNA, the identification of genetic variants that affect risk of Alzheimer's disease. PLoS One 2011 0.84
109 Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One 2013 0.84
110 The Notch-1 intracellular domain is found in sub-nuclear bodies in SH-SY5Y neuroblastomas and in primary cortical neurons. Neurosci Lett 2007 0.84
111 Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. Am J Med Genet B Neuropsychiatr Genet 2003 0.83
112 Dementia in Down's syndrome: an MRI comparison with Alzheimer's disease in the general population. J Neurodev Disord 2013 0.83
113 Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2005 0.83
114 Hyperphosphorylation of tau and neurofilaments and activation of CDK5 and ERK1/2 in PTEN-deficient cerebella. Mol Cell Neurosci 2007 0.83
115 Searching for biomarkers in neurodegeneration. Nat Med 2010 0.82
116 Genes related to vascular disease (APOE, VLDL-R, DCP-1) and other vascular factors in late-life depression. Am J Geriatr Psychiatry 2004 0.82
117 Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD. Am J Med Genet B Neuropsychiatr Genet 2004 0.82
118 Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. Neurosci Lett 2004 0.82
119 Evidence against roles for phorbol binding protein Munc13-1, ADAM adaptor Eve-1, or vesicle trafficking phosphoproteins Munc18 or NSF as phospho-state-sensitive modulators of phorbol/PKC-activated Alzheimer APP ectodomain shedding. Mol Neurodegener 2007 0.81
120 Alzheimer's Disease, Diagnosis and the Need for Biomarkers. Biomark Insights 2008 0.81
121 Complement factor H Y402H polymorphism is not associated with late-onset Alzheimer's disease. Neuromolecular Med 2007 0.81
122 Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiol Aging 2013 0.80
123 Education, occupation and retirement age effects on the age of onset of Alzheimer's disease. Int J Geriatr Psychiatry 2010 0.80
124 Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. J Transl Med 2012 0.80
125 The impact of a novel apolipoprotein E and amyloid-β protein precursor-interacting protein on the production of amyloid-β. J Alzheimers Dis 2011 0.79
126 Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. Neuroimage 2011 0.79
127 Out of sight out of mind? Support and information given to distant and near relatives of those with dementia. Int J Geriatr Psychiatry 2002 0.78
128 Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium. Medicine (Baltimore) 2016 0.78
129 Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegener Dis 2015 0.78
130 Transcriptomic profiles of Wnt3a and insulin in primary cultured rat cortical neurones. J Neurochem 2011 0.78
131 Clusterin as an Alzheimer biomarker. Arch Neurol 2011 0.77
132 Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment. Brain Topogr 2011 0.77
133 The clinical phenotype of familial and sporadic late onset Alzheimer's disease. Int J Geriatr Psychiatry 2002 0.77
134 The thiazolidinedione pioglitazone increases cholesterol biosynthetic gene expression in primary cortical neurons by a PPARgamma-independent mechanism. J Alzheimers Dis 2010 0.75
135 Harnessing clinical psychiatric data with an electronic assessment tool (OPCRIT+): the utility of symptom dimensions. PLoS One 2013 0.75
136 School students as Drosophila experimenters. PLoS Biol 2005 0.75
137 Psychotic genes or forgetful ones? Neurology 2002 0.75
138 Are abnormal premorbid personality traits associated with Alzheimer's disease? - A case-control study. Int J Geriatr Psychiatry 2010 0.75
139 Correction to "Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease". J Proteome Res 2016 0.75
140 Giving dementia a voice. Ment Health Today 2010 0.75
141 Polymorphisms in the phosphate and tensin homolog gene are not associated with late-onset Alzheimer's disease. Neurosci Lett 2006 0.75
142 Genetics and dementia nosology. J Geriatr Psychiatry Neurol 2006 0.75